GlassScriptPhysician profile
Casey Shannon Hatfield
NPI 1710456561
$3,590.36
in general payments reported to CMS, 2019-2025
31 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $766 · 2022: $325 · 2023: $289 · 2024: $943 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $754.92 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $518.20 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $316.62 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $277.53 | 2021-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $262.30 | 2023-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $245.19 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $181.95 | 2024-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $178.77 | 2021-2025 | Fanapt |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $150.54 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $123.40 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $103.73 | 2025 | Cobenfy |
| Novo Nordisk INC | $45.93 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.76 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.99 | 2021-2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $37.45 | 2022-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $35.80 | 2025 | Jornay Pm |
| Amgen INC. | $28.48 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.86 | 2021 | |
| Intersect Ent, INC. | $25.53 | 2021 | |
| Dexcom, INC. | $23.02 | 2021 | |
| Axsome Therapeutics, INC. | $21.44 | 2025 | Auvelity |
| Daiichi Sankyo INC. | $19.47 | 2021 | |
| Indivior INC. | $16.82 | 2024 | Perseris |
| Glaxosmithkline, LLC. | $16.63 | 2021 | |
| Almatica Pharma LLC | $16.33 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.15 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.83 | 2021 | |
| Mylan Specialty L.P. | $12.72 | 2021 | |
| Avanir Pharmaceuticals, INC. | $12.27 | 2021 | |
| Amarin Pharma, INC. | $11.49 | 2021 | |
| Esperion Therapeutics, INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Hatfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.